{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:17:29Z","timestamp":1740107849369,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We present a case of an ultimately fatal course of COVID-19 (coronavirus disease-19) in an 81-year-old female patient during the Omicron surge. The patient did not represent the typical patient at risk for severe COVID-19 with significant causes of immunodeficiency. However, she had been skeptical about the vaccination for severe acute respiratory syndrome virus-2 (SARS-CoV-2) and had refused it. Moreover, there had been no previous COVID-19 episodes. Our case report illustrates that with regard to SARS-CoV-2, immunologically naive patients are still at risk for severe and\/or even fatal courses of COVID-19. We call to implement both, recommendations for SARS-CoV-2 vaccinations as well as for antiviral treatment.<\/jats:p>","DOI":"10.1007\/s15010-023-02120-w","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T18:02:03Z","timestamp":1699293723000},"page":"271-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A fatal course of COVID-19 during the Omicron surge: can you estimate your patients\u2019 SARS-CoV-2 immune status?"],"prefix":"10.1007","volume":"52","author":[{"given":"Martin","family":"Mersch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schlabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Breitschwerdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Laufenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorian","family":"Emmert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souhaib","family":"Aldabbagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Boesecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8794-3612","authenticated-orcid":false,"given":"Malte Benedikt","family":"Monin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"2120_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.18690","volume":"201","author":"M Mikulska","year":"2023","unstructured":"Mikulska M, Testi D, Russo C, Balletto E, Sepulcri C, Bussini L, Dentone C, Magne F, Policarpo S, Campoli C, Miselli F, Cilli A, Ghiggi C, Aquino S, Di Grazia C, Giannella M, Giacobbe DR, Vena A, Raiola AM, Bonifazi F, Zinzani P, Cavo M, Lemoli R, Angelucci E, Viale P, Bassetti M, Bartoletti M. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders. Br J Haematol. 2023;201:628\u201339. https:\/\/doi.org\/10.1111\/bjh.18690.","journal-title":"Br J Haematol"},{"key":"2120_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02081-0","author":"YR H\u00fcbner","year":"2023","unstructured":"H\u00fcbner YR, Spuck N, Berger M, Schlabe S, Rieke GJ, Breitschwerdt S, van Bremen K, Strassburg CP, Gonzalez-Carmona MA, Wasmuth JC, Rockstroh JK, Boesecke C, Monin MB. Antiviral treatment of COVID-19: which role can clinical parameters play in therapy evaluation? Infection. 2023. https:\/\/doi.org\/10.1007\/s15010-023-02081-0.","journal-title":"Infection"},{"key":"2120_CR3","unstructured":"https:\/\/github.com\/robert-koch-institut\/COVID-19-Impfungen_in_Deutschland\/blob\/main\/Deutschland_Impfquoten_COVID-19.csv (Access: Sep13, 2023)"},{"key":"2120_CR4","unstructured":"Robert Koch-Institut. Monitoring des COVID-19-Impfgeschehens in Deutschland. Monatsbericht vom 04.05.2023. Online verf\u00fcgbar unter: www.rki.de\/covid-19-impfbericht."},{"key":"2120_CR5","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1016\/j.vaccine.2023.05.015","volume":"41","author":"K Ishikawa","year":"2023","unstructured":"Ishikawa K, Nascimento MC, Asano M, Hirata H, Itoh Y, Kelly EJ, Matsui A, Olsson U, Shoemaker K, Green J. One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): final analysis of a randomized, placebo-controlled phase \u00bd trial in Japan. Vaccine. 2023;41:4199\u2013205. https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.015.","journal-title":"Vaccine"},{"key":"2120_CR6","doi-asserted-by":"publisher","unstructured":"St\u00e4ndige Impfkommission: Beschluss der STIKO zur 25. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2023;8:3\u201321. https:\/\/doi.org\/10.25646\/11151.","DOI":"10.25646\/11151"},{"key":"2120_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25646\/11461.3","volume":"21","author":"J Koch","year":"2023","unstructured":"Koch J, Piechotta V, Berner R, Bogdan C, Burchard G, Heininger U, Hummers E, von Kries R, Ledig T, Littmann M, Meerpohl J, Mertens T, R\u00f6bl-Mathieu M, van der Sande M, Sander LE, Terhardt M, \u00dcberla K, Vygen-Bonnet S, Wichmann O, Wicker S, Wiedermann- Schmidt U, Widders G, Zepp F. Empfehlung der STIKO zur Implementierung der COVID-19-Impfung in die Empfehlungen der STIKO 2023 und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung. Epid Bull. 2023;21:7\u201348. https:\/\/doi.org\/10.25646\/11461.3.","journal-title":"Epid Bull"},{"key":"2120_CR8","volume-title":"Therapeutics and COVID-19: living guideline, 14 July 2022","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Therapeutics and COVID-19: living guideline, 14 July 2022. Geneva: World Health Organization; 2022."},{"key":"2120_CR9","unstructured":"Kluge S, Janssens U, Welte T, Weber-Carstens S, Sch\u00e4lte G, Spinner CD, Malin JJ, Gastmeier P, Langer F, Bracht H, Westhoff M, Pfeifer M, Rabe KF, Hoffmann F, B\u00f6ttiger BW, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Haase R, M\u00fcller OJ, Specker C, Nothacker M, Skoetz N, Marx G, Karagiannidis C. S3-Leitlinie - Empfehlungen zur Therapie von Patienten mit COVID-19 (2023)."},{"key":"2120_CR10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s15010-023-01994-0","volume":"51","author":"L Pilgram","year":"2023","unstructured":"Pilgram L, Appel KS, Ruethrich MM, Koll CEM, Vehreschild MJGT, de Miranda SMN, Hower M, Hellwig K, Hanses F, Wille K, Haselberger M, Spinner CD, Vom Dahl J, Hertenstein B, Westhoff T, Vehreschild JJ, Jensen BO, Stecher M. Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. Infection. 2023;51:1033\u201349. https:\/\/doi.org\/10.1007\/s15010-023-01994-0. (Epub 2023 Feb 10).","journal-title":"Infection"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02120-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T10:10:55Z","timestamp":1706177455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02120-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2120"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02120-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"type":"print","value":"0300-8126"},{"type":"electronic","value":"1439-0973"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"16 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM declares no conflicts of interest. SS had a stipend from the German Centre for Infectious Diseases Research (DZIF); he received congress fees and travel expenses from Gilead, Abbvie, and Johnson&Johnson, and funding from the German Research Society (DFG) for initiation of an African-German research project; he holds Fonds-based shares from BionTech. SB declares no conflicts of interest. JL declares no conflicts of interest. DE received honoraria for lectures from Gilead and holds stocks from BionTech. SA declares no conflicts of interest. CB received honoraria for lectures and\/or consultancies from AbbVie, Gilead, Janssen, MSD, ViiV, and funding from Dt. Leberstiftung, DFG, DZIF, Hector Stiftung, NEAT ID. MBM received honoraria for lectures, travel expenses, and\/or consultancies from Pfizer, Gilead Sciences, AstraZen- eca, NovaVax, and Virology Education. However, these activities have no potential conflicts of interest with the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Due to the retrospective study design, ethical approval and\/or patient information were not required according to the North Rhine-Westphalian legislation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The consent of the late patient's relatives was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publish statements"}}]}}